Home›Trilaciclib

Trilaciclib

Also known as: Cosela

Route: Intravenous

3 interactions on record

Trilaciclib has 3 known drug interactions based on U.S. FDA drug labeling data. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Cisplatin, Dalfampridine, Dofetilide. Patients taking Trilaciclib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 3
Major: 3

Major (3)

Trilaciclib + Cisplatin— COSELA may increase cisplatin exposure and kidney accumulation, causing dose-related nephrotoxicity. Close monitoring re…
Trilaciclib + Dalfampridine— COSELA inhibits OCT2 and may increase dalfampridine blood levels, elevating risk of seizures.
Trilaciclib + Dofetilide— COSELA inhibits OCT2 and may increase dofetilide concentration, causing serious ventricular arrhythmias and QT interval …

Trilaciclib + Cisplatin⚠️Major

COSELA may increase cisplatin exposure and kidney accumulation, causing dose-related nephrotoxicity. Close monitoring required.

Trilaciclib + Dalfampridine⚠️Major

COSELA inhibits OCT2 and may increase dalfampridine blood levels, elevating risk of seizures.

Trilaciclib + Dofetilide⚠️Major

COSELA inhibits OCT2 and may increase dofetilide concentration, causing serious ventricular arrhythmias and QT interval prolongation including torsade de pointes.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.